CA2615108A1 — Preservative composition for ophthalmic use
Assigned to Santen Pharmaceutical Co Ltd · Expires 2007-01-18 · 19y expired
What this patent protects
The object is to prevent the generation of chlorine dioxide in a liquid preparation for ophthalmic use containing a hypochlorite. A liquid preparation for ophthalmic use comprising a preservative composition for ophthalmic use which comprises a hypochlorite and at least one stabi…
USPTO Abstract
The object is to prevent the generation of chlorine dioxide in a liquid preparation for ophthalmic use containing a hypochlorite. A liquid preparation for ophthalmic use comprising a preservative composition for ophthalmic use which comprises a hypochlorite and at least one stabilizer selected from the following substances 1) to 7): 1) creatinine; 2) geraniol; 3) glucose; 4) tocopherol acetate; 5) oxiquinoline sulfate; 6) a sugar alcohol; and 7) a polyoxyethylene sorbitan fatty acid ester. The liquid preparation can prevent the generation of chlorine dioxide, and is therefore excellent in safety and shows a sustained preservative effect for a prolonged period of time.
Drugs covered by this patent
- Remodulin (TREPROSTINIL) · United Therap
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.